- Home
- KURA
KURA
Kura Oncology Inc.
as 07-26-2024 4:00pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.6B | IPO Year: | N/A |
| Target Price: | $28.36 | AVG Volume (30 days): | 846.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.41 - $24.17 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bair Teresa Brophy | KURA | Chief Legal Officer | May 20 '24 | Sell | $22.15 | 2,615 | $57,916.24 | 68,979 | SEC Form 4 |
| DALE STEPHEN | KURA | Chief Medical Officer | Jan 29 '24 | Sell | $21.55 | 4,825 | $103,979.72 | 38,817 | SEC Form 4 |
| DALE STEPHEN | KURA | Chief Medical Officer | Jan 29 '24 | Sell | $17.80 | 2,758 | $49,093.78 | 43,642 | SEC Form 4 |
| DALE STEPHEN | KURA | Chief Medical Officer | Jan 29 '24 | Sell | $17.80 | 4,400 | $78,322.20 | 46,400 | SEC Form 4 |
| DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Jan 29 '24 | Sell | $17.80 | 594 | $10,573.50 | 49,817 | SEC Form 4 |
| DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Jan 29 '24 | Sell | $17.80 | 761 | $13,546.18 | 49,056 | SEC Form 4 |
| DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Jan 29 '24 | Sell | $17.80 | 963 | $17,141.88 | 48,093 | SEC Form 4 |
| FORD KATHLEEN | KURA | Chief Operating Officer | Jan 29 '24 | Sell | $17.80 | 1,496 | $26,629.55 | 21,602 | SEC Form 4 |
| Bair Teresa Brophy | KURA | Chief Legal Officer | Jan 29 '24 | Sell | $17.80 | 2,053 | $36,544.43 | 68,979 | SEC Form 4 |
| WILSON TROY EDWARD | KURA | President and CEO | Jan 24 '24 | Sell | $20.23 | 6,945 | $140,497.35 | 559 | SEC Form 4 |
| WILSON TROY EDWARD | KURA | President and CEO | Jan 24 '24 | Sell | $20.23 | 84,107 | $1,701,484.61 | 559 | SEC Form 4 |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
22 days ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
23 days ago
Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
GlobeNewswire
a month ago
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
GlobeNewswire
2 months ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Kura Oncology to Participate in Jefferies Global Healthcare Conference
MT Newswires
2 months ago
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug
GlobeNewswire
2 months ago
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
Motley Fool
3 months ago
2 Incredible Growth Stocks to Buy Hand Over Fist
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.